<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________
FORM 10-Q
__________________
(Mark One)
X Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
- -- Act of 1934
FOR THE QUARTER ENDED SEPTEMBER 30, 1996
OR
Transition report pursuant to Section 13 or 15(d) of the Securities
- -- Exchange Act of 1934
COMMISSION FILE NUMBER: 0-27242
PHYSIO-CONTROL INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 91-1673799
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
11811 WILLOWS ROAD N.E.
REDMOND, WASHINGTON 98052
(Address of principal executive offices)
(206) 867-4000
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days:
Yes X No
--- ---
As of October 25, 1996, there were 16,910,107 shares of the Registrant's
Common Stock outstanding.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 2
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Form 10-Q
September 30, 1996
<TABLE>
<CAPTION>
Index Page
----- ----
<S> <C>
PART I. FINANCIAL INFORMATION
ITEM 1. Consolidated Financial Statements
- Consolidated Statements of Operations for the three months
ended September 30, 1996 and 1995 and for the nine months
ended September 30, 1996 and 1995. . . . . . . . . . . . . . . . . . . . . 3
- Consolidated Balance Sheets as of September 30, 1996
and December 31, 1995. . . . . . . . . . . . . . . . . . . . . . . . . . . 4
- Consolidated Statement of Changes in Stockholders' Equity
for the nine months ended September 30, 1996 . . . . . . . . . . . . . . . 5
- Consolidated Statements of Cash Flows for the nine months
ended September 30, 1996 and 1995. . . . . . . . . . . . . . . . . . . . . 6
- Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . 7
ITEM 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
ITEM 6. Exhibits and Reports on Form 8-K. . . . . . . . . . . . . . . . . . . . . . . . 12
</TABLE>
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 3
PART I. Financial Information
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
(DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
THREE MONTHS ENDED SEPTEMBER 30, NINE MONTHS ENDED SEPTEMBER 30,
1996 1995 1996 1995
----------- ------------ ------------- ------------
(UNAUDITED) (UNAUDITED) (UNAUDITED)
<S> <C> <C> <C> <C>
Net sales $41,694 $34,733 $127,372 $108,271
Cost of sales 20,141 16,295 62,288 51,158
------- ------- -------- -------
Gross profit 21,553 18,438 65,084 57,113
------- ------- -------- -------
Research and development 5,020 4,924 14,227 13,716
Sales and marketing 8,192 7,635 24,029 21,834
General and administrative 3,172 2,530 9,291 8,878
Management consulting fees -- 983 -- 2,950
------- ------- -------- -------
Operating expense 16,384 16,072 47,547 47,378
------- ------- -------- -------
Interest expense (459) (623) (1,333) (2,160)
Other (expense) income, net (331) 40 (789) (196)
------- ------- -------- -------
Other expense (790) (583) (2,122) (2,356)
------- ------- -------- -------
Income before income taxes 4,379 1,783 15,415 7,379
Income tax expense (1,488) (614) (5,241) (2,570)
------- ------- -------- -------
Net income $2,891 $1,169 $10,174 $4,809
------- ------- -------- -------
------- ------- -------- -------
(UNAUDITED)
Net earnings per common and
common equivalent share $0.16 $0.57
Weighted average number of common
and common equivalent shares outstanding 18,083,182 17,971,691
Pro forma net earnings per common
and common equivalent share $0.07 $0.31
Pro forma weighted average number of common
and common equivalent shares outstanding 15,759,194 15,523,876
</TABLE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
- -------------------------------------------------------------------------
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 4
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
CONSOLIDATED BALANCE SHEETS
(DOLLARS IN THOUSANDS, EXCEPT SHARE DATA)
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
SEPTEMBER 30, 1996 DECEMBER 31, 1995
------------------ -----------------
(UNAUDITED)
<S> <C> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents $4,255 $4,575
Accounts receivable, net 32,285 27,130
Inventories 33,310 30,208
Prepaid income taxes -- 2,637
Prepaid expenses 1,115 1,044
Deferred income taxes 3,179 2,790
------- -------
Total current assets 74,144 68,384
NONCURRENT ASSETS
Debt issue costs 115 151
Other assets 1,287 1,127
Deferred income taxes 3,124 3,124
Property, plant and equipment, net 10,775 5,714
------- -------
Total assets $89,445 $78,500
------- -------
------- -------
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $8,919 $10,109
Accrued liabilities 18,641 23,103
------- -------
Total current liabilities 27,560 33,212
------- -------
NONCURRENT LIABILITIES
Long-term debt 22,642 16,211
Unfunded pension obligations 1,947 2,396
------- -------
Total noncurrent liabilities 24,589 18,607
------- -------
Commitments and contingencies (Note 5)
STOCKHOLDERS' EQUITY
Preferred stock, par value $0.01 per share, 5,000,000
shares authorized, no shares issued or outstanding -- --
Common stock, voting, par value $0.01 per share,
40,000,000 shares authorized; 16,908,139 and
16,754,909 shares issued and outstanding, respectively 169 168
Additional paid-in capital 24,126 23,615
Retained earnings 12,933 2,759
Equity adjustment from foreign currency translation 68 139
------- -------
Total stockholders' equity 37,296 26,681
------- -------
Total liabilities and stockholders' equity $89,445 $78,500
- ----------------------------------------------------------------------- -------
- ----------------------------------------------------------------------- -------
</TABLE>
- ---------------------------------------------------------------------------
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 5
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
(DOLLARS IN THOUSANDS, EXCEPT SHARE DATA)
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
(UNAUDITED)
EQUITY
COMMON STOCK ADJUSTMENT
(VOTING) ADDITIONAL FROM FOREIGN
-------------------- PAID-IN RETAINED CURRENCY
SHARES DOLLARS CAPITAL EARNINGS TRANSLATION TOTAL
--------- ------- ---------- -------- ------------ -------
<S> <C> <C> <C> <C> <C> <C>
BALANCE AT DECEMBER 31, 1995 16,754,909 $168 $23,615 $2,759 $139 $26,681
Issuance of common shares 11,318 -- 212 -- -- 212
Stock issued upon exercise
of options 141,912 1 299 -- -- 300
Equity adjustment from
foreign currency translation -- -- -- -- (71) (71)
Net income -- -- -- 10,174 -- 10,174
---------- ------ -------- ------ ------ --------
BALANCE AT SEPTEMBER 30, 1996 16,908,139 $169 $24,126 $12,933 $68 $37,296
- --------------------------------------------- -------- -------- ---------- ------ --------
- --------------------------------------------- -------- -------- ---------- ------ --------
</TABLE>
- --------------------------------------------------------------------------
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 6
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
(DOLLARS IN THOUSANDS)
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
NINE MONTHS ENDED SEPTEMBER 30,
1996 1995
------------ ------------
(UNAUDITED)
<S> <C> <C>
Cash Flows From Operating Activities
Net income $10,174 $4,809
ADJUSTMENTS TO RECONCILE NET INCOME TO NET CASH
PROVIDED BY (USED IN) OPERATING ACTIVITIES:
Depreciation and amortization 1,090 1,193
Decrease (increase) in receivables (5,155) 20,958
Increase in inventories (3,102) (2,720)
Decrease (increase) in prepaid income taxes 2,637 (2,276)
Decrease (increase) in prepaid expense and other assets (408) 1,251
Decrease (increase) in deferred tax asset (389) 2,607
Decrease in accounts payable (1,190) (2,691)
Decrease in accrued and other liabilities (4,911) (2,356)
Decrease in income taxes payable -- (7,134)
------------ ------------
Net cash provided by (used in) operating activities (1,254) 13,641
------------ ------------
Cash Flows From Investing Activities
Acquisition of net assets, net of cash acquired -- (2,044)
Purchases of property, plant and equipment (5,938) (4,033)
------------ ------------
Net cash used in investing activities (5,938) (6,077)
------------ ------------
Cash Flows From Financing Activities
Net proceeds from issuance of common stock 512 --
Repayment of term debt -- (1,249)
Borrowings under revolving debt 47,242 10,000
Repayments on revolving debt (40,811) (18,250)
------------ ------------
Net cash provided by (used in) financing activities 6,943 (9,499)
------------ ------------
Effect of exchange rate changes (71) 101
------------ ------------
Decrease in cash and cash equivalents (320) (1,834)
Cash and cash equivalents at beginning of period 4,575 5,229
------------ ------------
Cash and cash equivalents at end of period $4,255 $3,395
- ----------------------------------------------------------------------- ------------
- ----------------------------------------------------------------------- ------------
</TABLE>
- -------------------------------------------------------------------------
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 7
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 1996
(DOLLARS IN THOUSANDS)
- --------------------------------------------------------------------------------
(UNAUDITED)
NOTE 1. GENERAL
The consolidated financial statements of Physio-Control International
Corporation (the "Company") at September 30, 1996 and for the three and nine
month periods then ended are unaudited and reflect all adjustments (consisting
only of normal recurring adjustments) which are, in the opinion of management,
necessary for a fair presentation of the financial position and operating
results for the interim period. The consolidated financial statements should be
read in conjunction with the Company's Annual Report to Shareholders
incorporated by reference on Form 10-K for the fiscal year ended December 31,
1995. The results of operations for the three and nine month periods ended
September 30, 1996 are not necessarily indicative of the results for the entire
fiscal year ending December 31, 1996.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
EARNINGS PER SHARE
Net earnings per common and common equivalent share is computed using the
weighted average number of shares outstanding adjusted for the incremental
shares attributed to outstanding options to purchase common stock. Fully
diluted net earnings per common and common equivalent share is not materially
different from primary net earnings per common and common equivalent share and
is therefore not presented.
As a result of the changes in the Company's capital structure effective with the
initial public offering in December 1995, historical earnings per common share
amounts would not be meaningful and therefore, have not been presented in these
financial statements for the three and nine month periods ended September 30,
1995.
PRO FORMA EARNINGS PER SHARE
For purposes of calculating pro forma net earnings per share, the weighted
average number of shares outstanding has been calculated giving retroactive
effect to the equity recapitalization described in Note 11 of the Consolidated
Financial Statements included in the Company's Annual Report to Shareholders
incorporated by reference on Form 10-K for the fiscal year ended December 31,
1995.
RECENT ACCOUNTING PRONOUNCEMENT
During October 1995, the Financial Accounting Standards Board issued FAS 123,
"Accounting for Stock-Based Compensation", which established financial
accounting and reporting standards for stock-based employee compensation plans
and for the issuance of equity instruments to acquire goods and services from
nonemployees. The Company has not determined its method of adoption for the
fiscal year ended December 31, 1996.
RECLASSIFICATIONS
Certain amounts in the prior period have been reclassified to conform with the
current period presentation.
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 8
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
NOTE 3. INVENTORIES
Inventories consist of the following:
SEPTEMBER 30, 1996 DECEMBER 31, 1995
------------------ -----------------
Finished products $21,138 $16,504
Purchased parts and assemblies in process 7,924 7,884
Service parts 9,396 9,507
------------------ -----------------
38,458 33,895
Less-Inventory allowances (5,148) (3,687)
------------------ -----------------
Total inventories $33,310 $30,208
------------------ -----------------
------------------ -----------------
NOTE 4. STOCK OPTIONS
On January 30, 1996, the Company authorized the granting of 474,000 stock
options with an exercise price of $20.50 to 188 employees under the 1996 Stock
Incentive Plan. In addition, on May 23, 1996 the Company authorized the
granting of 24,000 stock options with an exercise price of $19.75 and on August
5, 1996, the Company authorized the granting of 400,500 options with an exercise
price of $15.38. All options granted were at the fair-market value on that date
and vest in equal installments over a five year period.
NOTE 5: COMMITMENTS AND CONTINGENCIES
LITIGATION
The Company has been named as a defendant in several product lawsuits. The
Company has provided for its estimated exposure, including costs of litigation
with respect to all liability claims. The Company's estimates of these expenses
are based primarily on historical claims experience. The Company expects the
cash amounts related to these accruals to be paid out over the next several
years. The majority of the costs associated with defending and disposing of
these suits are covered by insurance. The Company's estimates of insurance
recoveries are based on existing deductibles and coverage limits.
Further, product liability claims may be asserted in the future for events not
currently known by management. Although the ultimate liability from these
potential claims cannot be ascertained at September 30, 1996, management does
not anticipate that any related settlement, after consideration of potential
insurance recovery, would have a material adverse effect on the Company's
financial position, operating results or cash flows.
On November 13, 1995, the Company initiated litigation in Washington State Court
against Heartstream, Inc. ("Heartstream"), a company recently formed to develop
defibrillators, and certain individuals who were formerly employed by the
Company and are founders of and current employees of Heartstream. The Company's
claims are based on its belief that Heartstream and such individuals have, among
other things, misappropriated certain of the Company's intellectual property and
that such individuals have breached contractual obligations to the Company. The
Company received an answer to its complaint from Heartstream during December
1995. In its answer, Heartstream denies the Company's claims and alleges
certain counterclaims against the Company for, among other things,
monopolization of the industry and tortuous interference with business
opportunities and seeks monetary damages in excess of $10 million. The parties
are currently conducting discovery in this litigation. If the Company does not
prevail in this litigation or otherwise successfully resolve its claims, its
ability to design and market certain future products may be adversely affected.
In addition, if a court were to find in favor of Heartstream on its
counterclaims, the Company could be held liable for significant damages.
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 9
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
RESULTS OF OPERATIONS
THREE MONTHS ENDED SEPTEMBER 30, 1996 AND 1995
The Company reported worldwide sales of $41.7 million during the third quarter
of 1996, an increase of $7.0 million or 20% from the comparable 1995 quarter.
Domestic sales for the current quarter aggregated $31.6 million, up 21% from the
comparable 1995 quarter and international sales totaled $10.1 million, up 19%
from 1995. On a consolidated basis, equipment sales of $27.8 million increased
15% over the comparable quarter of 1995, mainly due to higher LIFEPAK-Registered
Trademark- 11 and LIFEPAK 9 shipments. Service and supplies revenue of $13.9
million increased 32% over the comparable quarter of 1995 with service revenue
of $6.6 million up 15% from the prior period and supplies (disposables and
accessories) of $7.3 million, up 53% from the third quarter of 1995 driven by
QUIK-COMBO-TM- electrode and LIFEPAK 11 accessory sales.
The 21% increase in domestic revenue was driven by sharply higher out-of-
hospital market sales of $12.8 million, up 34% from the comparable 1995 quarter,
primarily due to the strong demand for LIFEPAK 11 products. Hospital sales
aggregated $7.8 million or $0.5 million (6%) lower than the third quarter of
1995 largely due to timing of orders as hospital sales during the second quarter
of 1996 were up 15% from the second quarter of 1995. The 19% increase in
international revenue was largely attributed to higher sales of LIFEPAK 9
products.
During the third quarter of 1996, the Company reported product orders of $38.9
million, up $3.7 million or 11% from the comparable 1995 quarter due to
significant orders for the LIFEPAK 11 and LIFEPAK 9 products. Although domestic
product orders showed only modest growth from record orders received in the
third quarter of 1995, international product orders increased 41% over the
comparable 1995 quarter.
Gross profit of $21.6 million increased $3.1 million or 17% from the comparable
1995 quarter. As a percentage of sales, gross profit decreased slightly to
51.7% during the current quarter from 53.1% in the comparable 1995 quarter. The
decrease of 140 basis points in gross margin resulted primarily from a changing
product mix, including higher service and supply sales.
Research and development ("R&D") expenditures of $4.9 million for the third
quarter of 1996 increased $0.1 million from the comparable 1995 quarter. As a
percentage of sales, R&D expenses decreased to 12% during the current 1996
quarter from 14% during the comparable 1995 quarter. The Company's significant
investment in R&D activities reflect ongoing commitment to the development of
new products as well as advancing research for the development of future
products.
Selling, general and administrative ("SG&A") expenses of $10.2 million during
the third quarter of 1996 increased $1.2 million or 12% from the comparable 1995
quarter. The increase resulted primarily from costs incurred to further develop
and expand the Company's direct sales and service operations in Europe.
Domestic SG&A expenses, however, remained relatively constant during both
periods. As a percentage of sales, the Company's SG&A expenses decreased to 27%
during the current 1996 quarter from 29% during the comparable 1995 quarter.
Management consulting fees payable to Bain Capital, Inc. decreased $1.0 million
from the comparable quarter of 1995. The management consulting agreement was
terminated during 1995 and the fees associated with the contract were not
applicable during 1996.
Other expenses increased $0.2 million from the comparable 1995 quarter from $0.6
million in 1995 to $0.8 million in 1996. This increase is primarily attributed
to a non-recurring international expense during the third quarter of 1996.
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 10
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
As a result of the above factors, 1996 third quarter net income of $2.9 million
increased $1.7 million or 147% from the comparable 1995 quarter.
NINE MONTHS ENDED SEPTEMBER 30, 1996 AND 1995
The Company reported worldwide sales of $127.4 million during the nine month
period ended September 30, 1996, an increase of $19.1 million or 18% from the
comparable 1995 period. Domestic sales of $96.2 million were up $17.8 million
while international sales of $31.2 million were up $1.3 million from the
comparable 1995 period. On a consolidated basis, equipment sales of $85.7
million were up 13% during the current nine month period due primarily to
increased demand for the Company's family of LIFEPAK products. Worldwide
service revenue of $20.1 million increased 12% and supplies revenue of $21.5
million increased 46% from 1995, driven by QUIK-COMBO electrode and LIFEPAK 11
accessory product sales.
For the nine month period ending September 30, 1996, the 23% increase in
domestic revenue, when compared to the 1995 period, resulted from a 31% increase
in out-of-hospital equipment sales, mainly LIFEPAK 11, and from a 30% increase
in service and supplies revenue, mainly QUIK-COMBO electrodes and LIFEPAK 11
accessories. Domestic hospital equipment sales were up 4% over the comparable
1995 period. For the current nine month period, the 4% increase in
international revenue reflected a 16% increase in service and supplies revenue.
During the nine months ended September 30, 1996, worldwide product orders
totaled $106.7 million, an increase of $10.6 million or 11% over the comparable
prior year period. The increase in product orders resulted primarily from
strong demand for the LIFEPAK 11 products, and solid performance in the
international markets. International and domestic orders both increased 11%
over the comparable 1995 period. Conversely, product backlog at September 30,
1996 was $11.4 million, down $4.1 million from September 30, 1995 which reflects
a company-wide focus initiated during early 1996 to improve timeliness of
customer product deliveries.
Gross profit of $65.1 million increased $8.0 million or 14% for the nine month
period ended September 30, 1996 when compared to the prior 1995 period. As a
percentage of sales, gross profit decreased from 52.7% in the prior year period
to 51.1% in the current 1996 period, largely as a result of changes in product
mix as well as the Company's trade-in programs earlier in the year (resulting in
higher product discounts) which were targeted at an increasing market share.
R&D expenses for the nine months ended September 30, 1996 were $14.2 million, an
increase of $0.5 million or 4% over the comparable period in 1995. As a
percentage of sales, R&D expenses decreased from 13% in the comparable 1995
period to 11% during the current period.
SG&A expenses of $33.3 million for the nine months ended September 30, 1996
increased $2.6 million, or 8% from the comparable 1995 period. The increase
resulted from costs incurred to further develop the Company's direct sales and
service operations in Europe, as well as increased selling expense related to
higher sales volume in the current nine month period. As a percentage of sales,
SG&A expenses decreased to 26% during the current year period from 28% during
the prior year period.
Management consulting fees payable to Bain Capital, Inc. decreased $3.0 million
from the comparable 1995 period. During 1995, the management consulting
agreement was terminated and the fees associated with the contract are not
applicable in 1996.
Other expenses of $2.1 million decreased $0.3 million in the nine month period
ended September 30, 1996. The overall decrease resulted from lower interest
expense, mainly due to (i) a reduction of the Company's debt and (ii) lower
interest rates obtained as a result of refinancing the Company's debt during
December 1995.
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 11
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
As a result of the above factors, net income totaled $10.2 million for the nine
month period ended September 30, 1996, an increase of $5.4 million or 112% from
the comparable 1995 period.
LIQUIDITY AND CAPITAL RESOURCES
Management assesses the Company's liquidity by its ability to generate cash to
fund its operations. Significant factors in the management of liquidity are:
funds provided or used by operations; levels of accounts receivable,
inventories, accounts payable and capital expenditures; and adequate lines of
credit.
For the nine months ended September 30, 1996, the Company used $1.3 million in
cash to finance operations. The use of working capital funds was primarily
attributable to increased sales volume evidenced by higher accounts receivable
and inventories, partially offset by net income. The Company believes that,
based upon current levels of operations and anticipated growth, funds
generated from operations and available borrowings under the credit facility
described below, will be sufficient over the next twelve months for the
Company to make anticipated capital expenditures and fund working capital
requirements.
Cash used in investing activities during the nine months ended September 30,
1996 totaled $5.9 million and related to capital expenditures. Consistent with
the first half of 1996, primary capital expenditures during the current quarter
included software development costs for internal use software, purchases of
research equipment, and tooling for new products. The Company currently has no
capital commitments outside the ordinary course of business. The Company's
principal working capital requirements are financing accounts receivable and
inventories. At September 30, 1996, the Company had net working capital of
$46.6 million, including accounts receivable of $32.3 million, inventories of
$33.3 million, accounts payable of $8.9 million and accrued liabilities of $18.6
million.
During December 1995, the Company refinanced its existing indebtedness and
entered into the Amended and Restated Credit Agreement ("the Credit Agreement"),
which provides for a revolving credit facility ("the Revolver") not to exceed
$30.0 million. The revolver bears interest, at the Company's option, at either
(i) the lender's base rate (the higher of such lender's prime rate or the
federal funds rate plus 0.5%) or (ii) LIBOR plus 1.0%. Such rates are subject
to increase in the event that the Company does not meet certain leverage and
interest coverage ratios. At September 30, 1996, the average interest rate on
amounts outstanding under the Revolver was 6.7%. The Company's indebtedness
under the Revolver is secured by a first priority interest in and lien on all of
the assets of Physio-Control Corporation ("PCC"), a pledge by the Company on all
of the outstanding common stock of PCC and 65% of the outstanding stock of PCC's
subsidiaries and other guaranties and pledges as defined in the Credit
Agreement. The Credit Agreement includes various affirmative and negative
covenants which require, among other things, that the Company maintain certain
debt to equity and net worth ratios, limitations on capital expenditures,
restrictions on the declaration and payment of dividends and minimum earning
requirements. At September 30, 1996, the Company had borrowing availability of
approximately $9.9 million under the Revolver and was in compliance with all
related loan covenants of the Credit Agreement.
In addition, the Company has subordinated notes payable to Eli Lilly and Company
totaling $2.5 million which originated in the acquisition of PCC and certain
foreign operations. Notes with a principal balance totaling $1.5 million
mature on January 31, 2001 and bear interest at LIBOR plus 3.25%. A note with
a principal balance of $1.0 million matures November 15, 1998 and bears
interest at LIBOR plus 3.0%.
<PAGE>
PHYSIO-CONTROL INTERNATIONAL CORPORATION 12
- --------------------------------------------------------------------------------
The Company believes that, based upon current levels of operations and
anticipated growth, funds generated from operations, together with other
available sources of liquidity, including borrowings under the Revolver, will be
sufficient over the next twelve months for the Company to make anticipated
capital expenditures and fund working capital requirements.
Approximately 25% of the Company's sales in the nine months ended September 30,
1996 were to international customers and the Company expects that sales to
international customers will continue to represent a material portion of its
revenues. Certain of the Company's international receivables are denominated in
foreign currencies, and exchange rate fluctuations impact the carrying value of
these receivables. Historically, fluctuations in foreign currency exchange
rates have not had a material effect on the Company's results of operations and
the Company does not expect such fluctuations to be material in the foreseeable
future.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
There have been no material changes in the litigation reported in the Company's
Annual Report on Form 10-K for the year ended December 31, 1995, filed on March
29, 1996 except as reflected in the discussion under Note 5 of the Notes to
Consolidated Financial Statements in Part I, Item 1, above.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
EXHIBIT NO. DESCRIPTION OF EXHIBIT
27.1 Financial Data Schedule
No reports on Form 8-K were filed during the quarter ended September 30, 1996.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized to sign on behalf of the registrant and as
the principal financial officer thereof.
Dated: November 1, 1996
PHYSIO-CONTROL INTERNATIONAL CORPORATION
By /s/ Joseph J. Caffarelli
-------------------------------------
Joseph J. Caffarelli
Executive Vice President and Chief
Financial Officer
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> SEP-30-1996
<CASH> 4,255
<SECURITIES> 0
<RECEIVABLES> 32,285
<ALLOWANCES> 0
<INVENTORY> 33,310
<CURRENT-ASSETS> 74,144
<PP&E> 10,775
<DEPRECIATION> 0
<TOTAL-ASSETS> 89,445
<CURRENT-LIABILITIES> 27,560
<BONDS> 0
0
0
<COMMON> 169
<OTHER-SE> 37,127
<TOTAL-LIABILITY-AND-EQUITY> 89,445
<SALES> 127,372
<TOTAL-REVENUES> 127,372
<CGS> 62,288
<TOTAL-COSTS> 62,288
<OTHER-EXPENSES> 47,547
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 1,333
<INCOME-PRETAX> 15,415
<INCOME-TAX> 5,241
<INCOME-CONTINUING> 10,174
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 10,174
<EPS-PRIMARY> .57
<EPS-DILUTED> 0
</TABLE>
